

MATEX INTERNATIONAL LIMITED
(Company Registration No. 198904222M)
(Incorporated in the Republic of Singapore)

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 106,956,928
NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY**

1. INTRODUCTION

The Board of Directors (the “**Board**” or “**Directors**”) of Matex International Limited (the “**Company**”, and, together with its subsidiaries, the “**Group**”) wishes to announce that the Company is proposing to undertake a renounceable non-underwritten rights issue (the “**Rights Issue**”) of up to 106,956,928 new ordinary shares in the capital of the Company (the “**Rights Shares**”), at an issue price of S\$0.027 for each Rights Share (the “**Issue Price**”), on the basis of two (2) Rights Shares for every five (5) existing ordinary shares in the issued and paid-up capital of the Company (“**Shares**”) held by Entitled Shareholders (as defined herein) as at a date and time to be determined by the Board for the purpose of determining the entitlements of the Entitled Shareholders under the Rights Issue (the “**Record Date**”), fractional entitlements to be disregarded.

2. THE RIGHTS ISSUE

2.1. The principal terms of the Rights Issue are as follows:

Issue Price	:	S\$0.027
Discount	:	The Issue Price represents a discount of: (a) approximately 22.9% to the closing market price of S\$0.035 per Share on the Singapore Exchange Securities Trading Limited (the “ SGX-ST ”) on 30 October 2020 (being the last trading day on which the Shares were traded on the SGX-ST prior to the release of this announcement); and (b) approximately 17.5% to the theoretical ex-rights price (“ TERP ”)¹ of S\$0.033 per Share (calculated based on the closing market price of S\$0.035 per Share on the SGX-ST on 30 October 2020 (being the last trading day on which the Shares were traded on the SGX-ST prior to the release of this announcement)).
Allotment Ratio	:	The Rights Shares are proposed to be offered to Entitled Shareholders (as defined herein) on the basis of two (2) Rights Shares for every five (5) existing Shares held by them on the Record Date, fractional entitlements to be disregarded.
Use of Proceeds	:	Please refer to Paragraph 7 for further information on the use of proceeds.
Purpose of Rights Issue	:	The Company is undertaking the Rights Issue to repay the Shareholder Loan (as defined herein), and strengthen the Group’s financial position and capital base. The Rights Issue will also provide shareholders of the Company (“ Shareholders ”) with an opportunity to maintain their equity participation in the Company at a reasonable discount. Please refer to Paragraph 6 for further information.
Non-Underwritten Rights Issue	:	In view of the Irrevocable Undertaking (as defined herein) by Dr. Tan Pang Kee as set out in Paragraph 5.1, and the savings in costs enjoyed by the Company as a result of not having to bear any

		underwriting fees, and there being no minimum amount that must be raised from the Rights Issue, the Company has decided to proceed with the Rights Issue on a non-underwritten basis.
Status of the Rights Shares	:	The Rights Shares are payable in full upon acceptance and/or application and will, upon allotment and issue, rank <i>pari passu</i> in all respects with the Company's then existing Shares, save for any dividends, rights, allotments or other distributions, the record date for which falls on or before the date of allotment and issue of the Rights Shares.
Offer Information Statement	:	The terms and conditions of the Rights Issue may be subject to such changes as the Directors may deem fit. The final terms and conditions of the Rights Issue will be contained in the Offer Information Statement (" OIS ") and its accompanying documents to be lodged with the SGX-ST, acting as agent on behalf of the Monetary Authority of Singapore (" MAS "). The OIS will be despatched by the Company to Entitled Shareholders (as defined herein) in due course.
Odd Lots	:	Shareholders who hold odd lots of the Rights Shares, and who wish to trade in odd lots should note that they will be able to do so on the Unit Share Market. Shareholders should note that the market for trading of such odd lots of Shares may be illiquid. There is no assurance that the Shareholders who hold odd lots of Shares will be able to acquire such number of Shares required to make up a board lot, or to dispose of their odd lots (whether in part or in whole) on the SGX-ST's Unit Share Market.
Option to Scale Down	:	Depending on the level of subscription for the Rights Shares, the Company will, if necessary, scale down the subscription for the Rights Shares and/or excess applications for the excess Rights Shares by any Shareholder (if such Shareholder chooses to subscribe for its pro rata Rights Shares entitlement and/or apply for unsubscribed Rights Shares) to avoid placing the relevant Shareholder and parties acting in concert with him in the position of incurring a mandatory general offer obligation under the Singapore Code on Take-overs and Mergers (" Code ") as a result of other Shareholders not taking up their Rights Shares entitlement fully; or to avoid the transfer of a controlling interest in the Company, which is prohibited under Rule 803 of the SGX-ST's Listing Manual Section B: Rules of Catalyst (" Catalist Rules "), unless prior approval of Shareholders is obtained in a general meeting.

Note:

- (1) TERP is calculated based on the following formula, assuming the Rights Issue is fully subscribed:

$$\text{TERP} = \frac{(\text{Market capitalisation of the Company based on the last traded price} + \text{gross proceeds from the Rights Issue})}{\text{Number of Shares after completion of the Rights Issue}}$$

- 2.2. The allotment and issue of the Rights Shares is proposed to be made pursuant to the authority under the share issue mandate ("**Share Issue Mandate**") granted by the Shareholders at the Annual General Meeting of the Company held on 29 June 2020 ("**2020 AGM**"), pursuant to Section 161 of the Companies Act, Cap. 50 and Rule 806(2) of the Catalyst Rules.

- 2.3. The Share Issue Mandate, amongst others, authorises the Directors to allot and issue shares and convertible securities of not more than 100% of the total number of issued shares (excluding treasury shares) in the capital of the Company, of which the aggregate number of shares and convertible securities to be issued other than on a pro rata basis to existing Shareholders does not exceed 50% of the total number of issued shares (excluding treasury shares) in the capital of the Company.
- 2.4. As at the date of approval for the Share Issue Mandate, the Company's issued share capital comprised 267,392,320 Shares (excluding treasury shares). As such, the number of Shares that may be issued on a pro rata basis to Shareholders pursuant to the Share Issue Mandate is 267,392,320 Shares.
- 2.5. As the maximum number of Rights Shares to be issued pursuant to the Share Issue Mandate is 267,392,320 Rights Shares, and given that no Shares have been issued pursuant to the Share Issue Mandate since the 2020 AGM, the Company will not be seeking specific approval from the Shareholders for the Rights Issue as the basis of the Rights Issue falls within the limit of the Share Issue Mandate.
- 2.6. The Company has not undertaken any equity fund raising exercise in the last 12 months. No securities or equity interests of the Company have been issued for cash or securities within the twelve (12) months immediately preceding the date of this announcement.

3. ELIGIBILITY TO PARTICIPATE

- 3.1. The Company proposes to provisionally allot Rights Shares to all Shareholders who are eligible to participate in the Rights Issue ("**Entitled Shareholders**"), comprising Entitled Depositors and Entitled Scripholders (both as defined below), on the basis of their shareholdings as at the Record Date. Entitled Shareholders will be entitled to participate in the Rights Issue and receive the OIS together with the appropriate application forms and accompanying documents at their respective Singapore addresses as maintained with the records of the Central Depository (Pte) Limited ("**CDP**") or the Share Registrar (as defined below), as the case may be.

Entitled Depositors

- 3.2. Entitled Depositors are Shareholders with Shares standing to the credit of their securities accounts ("**Securities Accounts**") and whose registered addresses with CDP are in Singapore as at the Record Date or who have registered addresses outside Singapore and provided CDP with addresses in Singapore for the service of notices and documents not later than 5.00 p.m. (Singapore time) on the date falling three (3) market days prior to the Record Date ("**Entitled Depositors**"). Entitled Depositors will be provisionally allotted the Rights Shares on the basis of the number of Shares standing to the credit of their Securities Accounts with CDP as at 5.00 p.m. (Singapore time) on the Record Date.

Entitled Scripholders

- 3.3. Entitled Scripholders are Shareholders whose: (a) share certificates are not deposited with CDP; (b) Shares are registered in their own names; and (c) registered addresses with the Company's share registrar, RHT Corporate Advisory Pte. Ltd. (the "**Share Registrar**"), are in Singapore as at the Record Date or who have registered addresses outside Singapore and provided the Share Registrar with addresses in Singapore for the service of notices and documents not later than 5.00 p.m. (Singapore time) on the date falling three (3) market days prior to the Record Date and persons who have tendered to the Share Registrar valid transfers of their Shares and the certificates relating thereto for registration up to the Record Date ("**Entitled Scripholders**"). Entitled Scripholders will have to submit duly completed and stamped transfers in respect of Shares not registered in the name of CDP, together with all relevant documents of title, so as to be received up to 5.00 p.m. (Singapore time) on the Record Date by the Share Registrar, in order to be registered to determine the transferee's provisional allotments of Rights Shares entitlements.

Foreign Shareholders

- 3.4. The distribution of the OIS and its accompanying documents may be prohibited or restricted (either absolutely or subject to various securities laws requirements, whether legal or administrative, being complied with) in certain jurisdictions under the relevant securities laws of those jurisdictions. For practical reasons and in order to avoid any violation of the securities legislation applicable in countries other than Singapore, the Rights Shares will **NOT** be offered to Shareholders with registered addresses outside Singapore and who have not, at least three (3) market days prior to the Record Date, provided CDP or the Share Registrar, as the case may be, with addresses in Singapore for the service of notices and documents ("**Foreign Shareholders**"). The OIS to be issued for the Rights Issue and accompanying documents will not be despatched, lodged, registered or filed in any jurisdiction other than Singapore. Accordingly, Foreign Shareholders will not be entitled to participate in the Rights Issue. No provisional allotment of Rights Shares will be made to Foreign Shareholders and no purported acceptance thereof or application for any excess Rights Shares therefore by any Foreign Shareholder will be valid.
- 3.5. The OIS and its accompanying documents will also **NOT** be despatched to persons purchasing entitlements to Rights Shares through the book-entry (scripless) settlement system if their registered addresses with CDP are outside Singapore ("**Foreign Purchasers**"). Foreign Purchasers may not accept any "nil-paid" rights credited to their Securities Account unless the Company and its counsel are satisfied that such action would not result in the contravention of any registration or other legal requirement in any jurisdiction.
- 3.6. Entitlements to Rights Shares which would otherwise have been provisionally allotted to Foreign Shareholders will, if practicable to do so and at the absolute discretion of the Company, be sold "nil-paid" on the Catalist board of the SGX-ST ("**Catalist**"), as soon as practicable, after dealings in the provisional allotments of Rights Shares commence. Such sales may, however, only be effected if the Company, in its absolute discretion, determines that a premium can be obtained from such sales, after taking into account expenses to be incurred in relation thereto. The net proceeds from all such sales, after deduction of all expenses therefrom, will be pooled and thereafter distributed to Foreign Shareholders in proportion to their respective shareholdings or, as the case may be, the number of Shares entered against their names in the depository register maintained by CDP as at the Record Date and sent to them at their own risk by ordinary post. If the amount of net proceeds to be distributed to any single Foreign Shareholder is less than S\$10.00, such amount shall be dealt with as the Directors may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder shall have any claim whatsoever against the Company, the Directors, the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), the Share Registrar, or CDP and their respective officers in connection therewith.
- 3.7. Where the provisional allotments of Rights Shares are sold "nil-paid" on the Catalist, they will be sold at such price or prices as the Company may, in its absolute discretion, decide and no Foreign Shareholder shall have any claim whatsoever against the Company, the Directors, the Sponsor, the Share Registrar, or CDP and their respective officers in connection therewith. If such provisional allotments of Rights Shares cannot be sold or are not sold on the Catalist as aforesaid for any reason by such time as the SGX-ST shall have declared to be the last day for trading in the provisional allotments of Rights Shares, the new Shares represented by such provisional allotments will be allotted and issued to satisfy applications for excess Rights Shares or disposed of or dealt with in such manner as the Directors may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder shall have any claim whatsoever against the Company, the Directors, the Sponsor, the Share Registrar, or CDP and their respective officers in connection therewith.
- 3.8. **SHAREHOLDERS WITH REGISTERED ADDRESSES OUTSIDE SINGAPORE WHO WISH TO PARTICIPATE IN THE RIGHTS ISSUE SHOULD PROVIDE: (A) CDP AT 9 NORTH BUONA VISTA DRIVE, #01-19/20 THE METROPOLIS, SINGAPORE 138588; OR (B) THE SHARE REGISTRAR AT 30 CECIL STREET, #19-08 PRUDENTIAL TOWER, SINGAPORE 049712, AS THE CASE MAY BE, IN WRITING, WITH ADDRESSES IN SINGAPORE FOR THE SERVICE OF NOTICES AND DOCUMENTS, AT LEAST THREE (3) MARKET DAYS PRIOR TO THE RECORD DATE.**

Acceptance, Excess Application and Payment Procedures

- 3.9. Entitled Shareholders will be at liberty to accept in full or in part, decline or otherwise renounce or, in the case of Entitled Depositors only, trade (during the "nil-paid" rights trading period prescribed by the SGX-ST) their provisional allotments of the Rights Shares and will also be eligible to apply for Rights Shares in excess of their provisional allotments under the Rights Issue. Entitlements which are not allotted or taken up for any reason will be aggregated and issued to satisfy applications, if any, for excess Rights Shares or otherwise disposed of or dealt with in such manner as the Directors may, in their absolute discretion, deem fit in the interests of the Company, subject to applicable laws and the Catalist Rules.
- 3.10. Fractional entitlements to the Rights Shares will be disregarded in arriving at the Entitled Shareholders' entitlements and will, together with the provisional allotments which are not taken up for any reason, be aggregated and used to satisfy excess applications (if any), or otherwise dealt with in such manner as the Directors may in their absolute discretion, deem fit for the benefit of the Company, subject to applicable laws and the Catalist Rules.
- 3.11. In the allotment of excess Rights Shares, preference will be given to Entitled Shareholders for rounding of odd lots, and Directors and substantial Shareholders who have control or influence over the Company in connection with the day-to-day affairs of the Company or the terms of the Rights Issue, or have representation (direct or through a nominee) on the Board will rank last in priority for the rounding of odd lots and allotment of excess Rights Shares.
- 3.12. The Company will also not make any allotment and issue of any Rights Shares that will result in a transfer of controlling interest in the Company, which is prohibited under Rule 803 of the Catalist Rules, unless prior approval of Shareholders is obtained in a general meeting. The procedures for, and the terms and conditions applicable to, acceptances, renunciation and/or sales of the provisional allotments of the Rights Shares and for the applications for excess Rights Shares, including each different mode of acceptance or application and payment, will be contained in the OIS and the relevant application forms.

4. CONDITIONS FOR THE RIGHTS ISSUE

- 4.1. The Rights Issue is subject to, amongst others, the following:
- (a) the receipt of the listing and quotation notice from the SGX-ST (and such notice not having been withdrawn or revoked on or prior to the completion of the Rights Issue) for the dealing in, listing of and quotation for the Rights Shares on the Catalist and, if such approval is granted subject to conditions, such conditions being acceptable to the Company;
 - (b) the lodgement of the OIS together with all other accompanying documents (if applicable) with the SGX-ST, acting as an agent on behalf of the MAS; and
 - (c) all other necessary approvals, consents and/or waivers required from any person, financial institution or regulatory body or authority of Singapore or elsewhere under any and all agreements applicable to the Company and/or applicable laws for the Rights Issue and to give effect to the Rights Issue, being obtained and not having been withdrawn or revoked before the completion of the Rights Issue.
- 4.2. The Company will be making an application to the SGX-ST, through the Sponsor, for the listing of and quotation for the Rights Shares on the Catalist. An appropriate announcement will be made in due course when the Company receives the listing and quotation notice for the Rights Shares from the SGX-ST.
- 4.3. Thereafter, the Offer Information Statement will be lodged with SGX-ST and despatched by the Company to Entitled Shareholders in due course.

5. SUPPORT BY EXECUTIVE DIRECTOR AND CONTROLLING SHAREHOLDER AND SET-OFF AND SETTLEMENT ARRANGEMENT

- 5.1. As at the date hereof, the Company's Managing Director and Chief Executive Officer, Dr. Tan

Pang Kee who is also an Executive Director and controlling shareholder, is the legal and beneficial of 58,343,000 Shares, representing approximately 21.82% of the Company's existing issued and paid-up share capital. To demonstrate his support for the Rights Issue and his commitment to, and confidence in, the Group, Dr. Tan Pang Kee has, amongst others, irrevocably undertaken (the "**Irrevocable Undertaking**") to the Company as follows:

- (a) to subscribe for, where applicable, his pro rata entitlement of the Rights Shares and/or unsubscribed Rights Shares ("**Subscription Amount**") PROVIDED ALWAYS that if due to the Irrevocable Undertaking, Dr. Tan Pang Kee and his concert parties (as defined in the Code; being Dr. Tan Pang Kee, Tan Guan Liang, Tan Pang Sim, and Tan Pang Jang (the "**Concert Parties**") are placed in a position of incurring a mandatory general offer obligation under Rule 14 of the Code, the Company shall scale down his Subscription Amount and the resultant Rights Shares in such a manner so as to avoid placing them in such a position; and
- (b) not to sell, transfer or otherwise deal (as the case may be) with any of the Shares that he owns or controls as at the date of the Irrevocable Undertaking, during the period between the date thereof and the Record Date.

- 5.2. The subscription monies payable by Dr. Tan Pang Kee in respect of his Subscription Amount will be fully offset against the S\$0.8 million shareholder loan which he had extended to the Company for general working capital purposes (the "**Shareholder Loan**"). The Shareholder Loan is an interest-free loan which is reviewed by the Company on a half-yearly basis. As the subscription monies payable by Dr. Tan Pang Kee will be fully offset against the Shareholder Loan, Dr. Tan Pang Kee will not be required to provide any letter of confirmation of financial resources to pay for such subscription monies.
- 5.3. For the avoidance of doubt, Dr. Tan Pang Kee has not been offered additional terms or benefits in connection with his giving of the Irrevocable Undertaking set out above. His Irrevocable Undertaking is subject to the same conditions as set out in Paragraph 4.1.

6. RATIONALE FOR THE RIGHTS ISSUE

- 6.1. As was announced by the Company in its unaudited half-year financial statement and dividend announcement for the period ended 30 June 2020 ("**HY2020**") on 14 August 2020, the Group's term loans had increased from approximately S\$6.18 million as at 31 December 2019 to S\$8.03 million as at 30 June 2020, which excludes Dr. Tan Pang Kee's Shareholder Loan.
- 6.2. The Company is undertaking the Rights Issue to deleverage its balance sheet and through the added liquidity and reduced gearing, strengthen the financial position and capital base of the Group. This will enhance the Group's ability to formulate, strategise and execute its business plans as the market enters into the cyclical recovery cycle, which is expected to drive up both volumes and market prices. It will also provide the Group with greater financial capacity and flexibility to capitalise on any investment opportunities in a timely manner as and when such opportunities arise.
- 6.3. The Rights Issue will also provide Shareholders with an opportunity to further participate in the equity of the Company at a reasonable discount and will allow the Group to be less reliant on external sources of funding, thereby potentially incurring lower external funding expenses.

7. USE OF PROCEEDS

- 7.1. The Company intends to utilise the proceeds from the Rights Issue, to fully repay the Dr. Tan Pang Kee's Shareholder Loan, and strengthen the Group's financial position and capital base. The amount and percentage allocation of the use of proceeds for these purposes will depend on the amount of Rights Shares allocated to Dr. Tan Pang Kee and subscription of the Rights Shares by other Entitled Shareholders.
- 7.2. Assuming that no other Shares are issued before the Record Date, and all Entitled Shareholders subscribe and pay for their pro rata entitlements of Rights Shares ("**Maximum Subscription Scenario**"), up to 106,956,928 Rights Shares will be issued. Upon the allotment and issuance

of the Rights Shares, the Company will have an enlarged issued and paid-up share capital comprising 374,349,248 Shares, of which the Rights Shares would represent approximately 28.57%.

Maximum Subscription Scenario

- 7.3. In the Maximum Subscription Scenario, the number of Rights Shares to be issued and the estimated gross proceeds from the Rights Issue ("**Gross Proceeds**") is as follows:

Shareholder	Pro Rata Entitlement of Rights Shares	Aggregate Gross Proceeds
Dr. Tan Pang Kee	23,337,200	S\$630,104
Other Entitled Shareholders	83,619,728	S\$2,257,733
Total	106,956,928	S\$2,887,837

- 7.4. After deducting the estimated professional fees and related expenses of approximately S\$0.16 million, the net proceeds raised from the Rights Issue in the Maximum Subscription Scenario is expected to be approximately S\$2.73 million ("**Net Proceeds**").

- 7.5. The Company intends to use the Net Proceeds in the following manner:

Use of Net Proceeds	Allocation of Net Proceeds (S\$' million)	Approximate Allocation of Net Proceeds (%)
Repayment of Shareholder Loan	0.80	29.3
General working capital purposes	1.93	70.7
Total	2.73	100.0

- 7.6. The Company intends to utilise the Net Proceeds for general working capital purposes which includes, but not limited to, operating costs of the Group, payment of professional fees, payment of trade-related debts, and payment of staff salaries. The Company envisages more cash to be utilised for its operating activities as the Group is in its recovery and business expansion phase.
- 7.7. Pending the deployment of the Net Proceeds, the Net Proceeds may be deposited with banks and/or financial institutions, invested in short-term money market instruments and/or marketable securities, or used for any other purposes on a short-term basis as the Directors may deem appropriate in the interests of the Group.
- 7.8. The Company will make periodic announcements on the utilisation of the Net Proceeds as and when such proceeds are materially disbursed and whether such disbursements are in accordance with the use of proceeds as stated in the OIS, and provide a status report on the use of the Net Proceeds in the Company's annual report until such time the Net Proceeds have been fully utilised. Where the proceeds have been used for working capital, the Company will also provide a breakdown with specific details on the use of Net Proceeds for working capital in the announcements and status reports. Where there is a material deviation in the use of the Net Proceeds, the Company will announce the reasons for such deviation.

Minimum Subscription Scenario

- 7.9. In the Minimum Subscription Scenario, where only Dr. Tan Pang Kee subscribes for the Rights Shares in accordance with the Irrevocable Undertaking, the Gross Proceeds will be used entirely to set-off the Shareholder Loan. Professional fees and expenses relating to the Rights Issue will be paid out of the Company's existing resources as no fresh funds will be raised from the

issuance of the Rights Shares.

- 7.10. In the Minimum Subscription Scenario, 106,956,928 Rights Shares may be issued to Dr. Tan Pang Kee based on the Irrevocable Undertaking. However, issuing such number of Rights Shares to Dr. Tan Pang Kee will result in the Concert Parties incurring a mandatory general offer obligation under Rule 14 of the Code for all the Shares of the Company. Accordingly, Dr. Tan Pang Kee's application to subscribe for Rights Shares will be scaled from 106,956,928 to 29,629,630, resulting in Dr. Tan Pang Kee holding 87,972,630 Shares representing 29.62% of the enlarged issued and paid-up share capital of the Company. Collectively, the Concert Parties will hold 88,727,630 Shares representing 29.87% of the enlarged issued and paid-up share capital of the Company. Consequently, the Gross Proceeds in the Minimum Subscription Scenario will be S\$0.8 million, which will be used to fully set-off the Shareholder Loan.
- 7.11. Based on the reasonable opinion of the Directors as at the date of this announcement, there is no minimum amount which must be raised from the Rights Issue. In the event that the Company is unable to raise sufficient funds, the Company will source for alternative sources of funding, including but not limited to bank borrowings and Shareholders' loans.

8. WORKING CAPITAL

- 8.1. The Directors are of the opinion that after taking into consideration the Group's internal resources, operating cash flows, present banking facilities, and the Shareholder Loan, the working capital available to the Group is sufficient to meet its present requirements. Notwithstanding the above, the reasons for undertaking the Rights Issue are set out in Paragraph 6.
- 8.2. The Group is now in its business recovery and expansion phase. To achieve the long-term goals of the Group, the Company envisages a stronger capital base and more cash will be required for the reasons set out in Paragraph 6 and for general working capital purposes which includes, but not limited to, operating costs of the Group, payment of professional fees, payment of trade-related debts and payment of staff salaries. Consequently, the proceeds from the Rights Issue will help the Company achieve its goals and thereby enhance shareholder's value. Thus, the Directors believe that the Rights Issue is in the interests of the Company and its shareholders.

9. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

Save as disclosed in this announcement, none of the Directors or substantial Shareholders of the Company, as well as their respective associates, have any interests, direct or indirect, in the Rights Issue (other than through their respective shareholdings in the Company, if any).

10. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Rights Issue and the Group, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

11. FURTHER ANNOUNCEMENTS

Further announcements will be made by the Company in relation to the Rights Issue as and when appropriate.

12. CAUTIONARY STATEMENT

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. The completion of the Rights Issue are subject to certain conditions. As at the

date of this announcement, there is no certainty or assurance that the Rights Issue will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board

Dr. Tan Pang Kee
Managing Director and Chief Executive Officer
30 October 2020

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**") in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst (the "**Catalist Rules**").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Jason Chian, Managing Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.